Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New agents for endocrine resistance in breast cancer.

Breast (Edinburgh, Scotland) - 1 Aug 2017

Maurer Christian, Martel Samuel, Zardavas Dimitrios, Ignatiadis Michail

Abstract excerpt

Estrogen receptor positive (ER+) and HER2-negative (HER2-) breast cancer (BC) is the most common BC subtype, defined by expression of the ER and absence of HER2 amplification. Endocrine treatment (ET), aiming at therapeutic blockade of ER signaling, represents the therapeutic mainstay for patients with both early and advanced disease. Despite its wide therapeutic efficacy, ET fails for a proportion of ER+, HER2-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Cyclin-Dependent Kinase 4
Share to Cyclin-Dependent Kinase 6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Histone Deacetylase Inhibitors

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Receptor, ErbB-2

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 28448864
DOI: 10.1016/j.breast.2017.04.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New agents for endocrine resistance in breast cancer.PMID 28448864Read ↗

Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.Semantic proximity Read ↗

Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance.Semantic proximity Read ↗

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.Semantic proximity Read ↗

Targeted therapies for ER+/HER2- metastatic breast cancerSemantic proximity Read ↗

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast CancerSemantic proximity Read ↗

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic ApproachesSemantic proximity Read ↗

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read ↗

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceSemantic proximity Read ↗

Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.Semantic proximity Read ↗

Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a reviewSemantic proximity Read ↗

Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goalsSemantic proximity Read ↗

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.